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AbsTrACT
Objective lack of standardised outcomes hampers 
effective analysis and comparison of data when 
comparing treatments in istulising perianal crohn’s 
disease (pcD). Development of a standardised set of 
outcomes would resolve these issues. this study provides 
the deinitive core outcome set (cOS) for istulising pcD.
Design candidate outcomes were generated through 
a systematic review and patient interviews. consensus 
was established via a three-round Delphi process using 
a 9-point likert scale based on how important they felt 
it was in determining treatment success culminating in 
a inal consensus meeting. Stakeholders were recruited 
nationally and grouped into three panels (surgeons 
and radiologists, gastroenterologists and iBD specialist 
nurses, and patients). Participants received feedback from 
their panel (in the second round) and all participants (in 
the third round) to allow reinement of their scores.
results a total of 295 outcomes were identiied from 
systematic reviews and interviews that were categorised 
into 92 domains. 187 stakeholders (response rate 
78.5%) prioritised 49 outcomes through a three-round 
Delphi study. the inal consensus meeting of 41 experts 
and patients generated agreement on an eight domain 
cOS. the cOS comprised three patient-reported outcome 
domains (quality of life, incontinence and a combined 
score of patient priorities) and ive clinician-reported 
outcome domains (perianal disease activity, development 
of new perianal abscess/sepsis, new/recurrent istula, 
unplanned surgery and faecal diversion).
Conclusion a istulising pcD cOS has been produced 
by all key stakeholders. application of the cOS will 
reduce heterogeneity in outcome reporting, thereby 
facilitating more meaningful comparisons between 
treatments, data synthesis and ultimately beneit patient 
care.
InTrODuCTIOn
The management of fistulising perianal Crohns 
disease (pCD) remains challenging. Fistulas are 
often complex in nature, and recurrence after 
treatment is common. Perianal manifestations of 
Crohns disease are recognised in the Montreal 
classification as a distinct phenotype1 from luminal 
disease. Fistulising pCD is associated with signifi-
cant morbidity and reduced quality of life.2 The 
established treatment pathway is multidisciplinary3 
and involves management of proctitis and drainage 
of sepsis, prior to optimisation of medical treat-
ment, usually with a combination of thiopurine and 
antitumour necrosis factor (TNF) therapies.4 Initial 
drainage of sepsis and placement of loose setons 
are the mainstay of surgical treatment, although 
reparative surgery aimed at fistula closure may 
be offered in selected patients, and defunctioning 
stoma or proctectomy may sometimes be required. 
Undrained ongoing perianal sepsis, injudicious 
surgery and recurrent perianal sepsis may all result 
in a poor functional outcome for the patient.
There has been significant recent innovation in 
managing fistulising pCD both in biological therapy 
with trials studying fistula healing as a primary 
outcome measure5 and in the introduction of 
novel, sphincter preserving techniques68 as well 
as modification of existing operations, such as the 
BioLIFT9 or LIFT-Plug.10 There are restrictions in 
the current literature that impair evidence synthesis 
and meta-analysis. One limitation is a lack of stan-
dardised outcome measurement, which hampers 
signiicance of this study
What is already known on this subject?
 Ź There is heterogeneity in the outcome measures 
used in interventional studies in istulising 
perianal Crohn’s disease. This limits meta-
analysis and other methods for comparing 
treatment options in this disease.
What are the new indings?
 Ź The generation of a patient-centred core 
outcome set (COS) based on the principles 
set out by the Core Outcome Measures in 
Effectiveness Trials (COMET) initiative and using 
a Delphi consensus of stakeholders including 
patients and clinicians who regularly manage 
istulising perianal Crohn’s disease.
How might it impact on clinical practice in the 
foreseeable future?
 Ź This COS will form the basis of outcome 
measurement in future interventional studies of 
istulising perianal Crohn’s disease.
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effective analysis and comparison of techniques and leads to a 
high risk of reporting bias.11 Most importantly, the currently 
used outcomes lack relevance to patients.
Measuring success or failure should not be determined by 
researchers alone, and the views of patients and other health-
care professionals involved in the care of patients with peri-
anal Crohns fistula must be considered. The Core Outcome 
Measures in Effectiveness Trials (COMET; www. comet- initia-
tive. org/ initiative) initiative has improved understanding of 
outcome reporting and standardised outcome reporting through 
the development of core outcome sets (COS). COSs are the 
minimum outcomes that should be reported in every study of a 
given condition.12 They have usually been informed by a system-
atic review and developed through a Delphi consensus process 
with key stakeholders.
COS are not restrictive; triallists may choose to investi-
gate other outcomes but should always include the COS as a 
minimum within their study design. New COS are increasingly 
being developed,13 and they are widely recognised in a number 
of specialties, such as rheumatology,14 paediatric surgery15 and 
colorectal surgery.16 Increasingly, funding bodies advocate the 
inclusion of COS within proposed trial methodology16 and 
uptake among triallists is increasing.17
The aim of this study was to develop a COS for fistulising 
pCD using Delphi methodology.
MeTHODs
Protocol registry
The development of this COS is based on the principles advised 
by the COMET initiative18 and reported in accordance with the 
Core Outcome Set-STAndards for Reporting (COS-STAR) State-
ment.19 This study has been registered with the COMET initia-
tive (www. comet- initiative. org).
scope
The scope of the COS is to include all medical treatments and 
surgical interventions used alone or in combination for adult 
patients with fistulising pCD. Most patients with Crohns fistula 
will undergo both medical and surgical interventions and studies 
usually follow a combined multidisciplinary stepwise approach, 
even when this is not explicit. The multimodal approach is used 
irrespective of whether the treatment intention is to induce 
fistula healing or palliate symptoms. A COS describes what 
outcomes should be measured but does not stipulate how they 
should be measured. It can be used for all types of study design, 
including audit.
Overview
In phase 1, a long list of candidate outcomes that could be 
measured in fistulising pCD trials was identified, and outcomes 
were categorised into domains.
In phase 2, outcome domains were presented via a web-based 
Delphi system that was used to assess key stakeholders views on 
the importance of each domain.
In phase 3, a consensus meeting with all stakeholders was used 
to finalise and ratify the COS.
Participants
Stakeholder representation was chosen to correlate with the 
clinical scenario since patients with perianal Crohns fistulas are 
managed by multidisciplinary teams, including surgeons, gastro-
enterologists, radiologists and IBD specialist nurses. Inclusion 
was limited to holding a consultant position or being on the IBD 
specialist nurse register.
All stakeholders were recruited through national organisa-
tions (and their subcommittees), and the study management 
group agreed that this should be limited to the UK to facilitate 
the process of ensuring equal though broad representation. The 
stakeholders were divided into three panels. Patients were given 
a panel to themselves as they were considered essential stake-
holders (box 1).
A participant information sheet was available on the webpage of 
the organisations and charities. On registration, participants were 
again provided with information about the survey and invited to 
complete an initial registration survey to capture demographic data. 
One reminder was sent if no response was received after 2 weeks. A 
purposive sampling technique was used to ensure variation based on 
geographical regions.
There are limited data to inform severity stratification or prog-
nostic classification of patients with Crohns fistula, an unmet 
need recognised internationally.20 After discussion within the 
study management group, it was decided that health states 
would be a more useful way of categorising patients.
Four groups were determined by the study management group 
to reflect the various health states patients with fistulising pCD 
patients may be in.
1. This is my first anal fistula causing me symptoms.
2. I've had at least one anal fistula before which got better but 
now I've got a new or newly symptomatic anal fistula.
3. I have had anal fistula in the past and currently. They never 
completely settle and always give me symptoms.
4. My fistula has healed following intervention.
We aimed to invite 180 experts to ensure 70 experts with a 
40% response rate. To maximise ongoing commitment to the 
process, we offered acknowledgement of participants completing 
all three rounds on publication of the study and sent newsletters 
after each of the Delphi rounds.
Information sources
A list of candidate outcomes were generated from a systematic 
literature review, interviews with patients, a dedicated patient 
box 1 stakeholder groups demonstrating the three 
panels
Panel sura
 Ź Colorectal surgeons (Su)
 – Association of Coloproctology of Great Britain and Ireland 
with a declared specialist interest in managing IBD.
 Ź Radiologists (Ra)
 – British Society of Gastrointestinal and Abdominal 
Radiology.
Panel Ganu
 Ź Gastroenterologists (Ga)
 – British Society of Gastroenterology IBD section.
 Ź IBD specialist nurses (Nu)
 – Royal College of Nursing regional and national network 
group of IBD nurses.
Panel Pa
 Ź Patients (Pa)
 – Crohn’s and Colitis United Kingdom, for Crohns, ‘St 
Mark’s Patient panel’, and Ileostomy Association (IA) (The 
ileostomy and internal pouch Support Group).
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and public involvement (PPI) meeting21 and the study manage-
ment group.
A systematic review of studies assessing medical, surgical 
and combined (medical/surgical) treatment of fistulising pCD 
was performed in accordance with a prospectively registered 
protocol (PROSPERO CRD42016039019).
The OVID SP version of MEDLINE (19502016) and Embase 
(19802016) were searched using validated terms for Crohns 
disease, anorectal fistula and randomized controlled trials or 
prospective studies separated by the Boolean operator AND 
(online supplementary file 1). This was supplemented with a 
free-text search of the same databases, using relevant keywords/
Table 1 Demographics of stakeholders
Participants characteristics 
registered participants (n=238) Consensus meeting (n=47)
Clinicians Patients Total Clinicians Patients Total
Gender
  Male 108 18 126 23 2 25
  Female 45 65 110 10 12 22
  Did not answer 2 0 2 0 0 0
Region
  Northern England 37 18 55 8 2 10
  Midland 22 8 30 5 1 6
  Southeast England 58 33 91 13 9 22
  Southwest England 20 8 28 3 2 5
  Wales 6 6 12 1 0 1
  Scotland 7 6 13 1 0 1
  Northern Ireland 2 3 5 2 0 2
  Did not answer 3 1 4 0 0 0
Type of hospital
  DGH 56 64 120 10 7 17
  Tertiary unit 97 17 114 23 7 30
  Private 1 1 0 0 0
  Other 1 1 0 0 0
  Did not answer 2 0 0 0 0 0
Other clinicians characteristics
  Length of consultant appointment (years)
   0–5 46 8
   6–10 34 4
   11–20 53 16
   >20 20 5
Other patient characteristics
  Age (years)
   20–29  32 3
   30–39  27 4
   40–49  17 5
   50–59  5 2
  Years with Crohn's disease (years) 
   0–5  25 4
   6–10  19 2
   11–20  24 6
   >20  15 2
  Years with anal istula (years) 
   0–5  52 2
   6–10  18 8
   11–20  11 2
   >20  1 0
   Did not answer 2
  Fistula status 
   First anal istula  24 2
   Previously healed anal istula, now new istula  12 2
   Recurrent anal istula  32 4
   Fistula healed following intervention  12 1
   Did not answer  0 5
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terms (including synonyms and variants), also separated by the 
Boolean operator AND. The search was limited to studies 
FRQGXFWHG LQKXPDQ DGXOWV DJHG\HDUV ROG DQG WRSDSHUV
published between 1 January 2010 and 12 July 2016, in order 
to ensure that identified outcomes were contemporary and 
currently applicable.
Prospective studies (including cohort comparisons, case 
controls and case series) that reported on outcomes on an 
intervention (medical, surgical and combination) for patients 
ZLWKILVWXOLVLQJS&'DQGUHFUXLWHGSDWLHQWVZHUHLQFOXGHG
Systematic reviews were included, and the individual studies 
reviewed were searched to ensure complete capture. Evaluation 
of luminal studies not primarily targeted at perianal fistulas were 
included where a subgroup analysis was presented for patients 
with fistula. Excluded were studies where the fistulas were of a 
non-Crohns aetiology, were not perianal or were not published 
in the English language.
Five independent reviewers (KS, SOA, PJT, MJL and NH) 
used predefined selection criteria to screen the studies, using 
Covidence Systematic Review Software (Veritas Health Inno-
vation, Melbourne, Australia; available at www. covidence. org). 
Each study was reviewed by at least two independent reviewers. 
Studies were initially screened in abstract format before full-text 
review. Conflicts were resolved by discussion with recourse to 
senior investigators (AH and NSF) where necessary.
Reported outcomes were extracted verbatim and listed in 
preparation for categorisation into domains.
Domain categorisation
Three members of the study team, two researchers (KS and PJT) 
and a patient representative (AV), categorised similar outcomes 
identified from the systematic review into domains by consensus. 
Four members of the study team (KS, PJT, SOA and AV) assessed 
and categorised the transcripts from the patient interviews and 
from the PPI meeting to supplement the list generated from the 
systematic review. All the included outcomes were categorised 
into themes and presented as such throughout the rest of the 
process.
Discrepancies were resolved through discussion with the 
senior authors (NF and AH). Overlapping domains between 
data sources were condensed, producing a final list of candi-
date outcomes. The study management group, consisting of all 
stakeholder groups, methodologists and patient representatives, 
then reviewed and finalised the domains. Outcomes that were 
felt to be solely applicable to luminal disease were excluded if 
all members of the study management group were in agreement.
The patient representatives (SB, AV) created plain English 
definitions for all outcomes under consideration. The long list of 
all possible outcomes was presented to the stakeholders through 
a web-based system purposefully designed to conduct a three-
phase Delphi process.
Consensus process
A three-round online Delphi process was used to prioritise 
outcomes. In each round, participants scored outcomes using 
the numerical scale suggested by the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) group 
(http://www. gradeworkinggroup. org). Scale 13 signified an 
outcome of limited importance (categorised as not important), 
46 signified important but not critical (categorised as fairly 
important) and 79 signified an outcome of critical impor-
tance (categorised as really important). In addition, a free-text 
space was provided for stakeholders to comment on the outcome 
definitions.
In round 1, participants were asked to score each outcome 
based on how important they felt it was in deciding whether the 
overall treatment of [their/their patients] pCD was successful 
and to suggest additional outcomes they felt were important 
but which had not previously been scored. All newly suggested 
outcomes were reviewed by the study management group and 
taken forward for assessment in the second round if within the 
scope of the COS.
In round 2, participants were asked to score the outcomes 
again having been shown numerical and graphical represen-
tations demonstrating how others in their panel scored each 
outcome in the first round. They were also shown their own 
response from the first round. In round 3, participants rescored 
the outcomes having been shown numerical and graphical repre-
sentations of how all panels scored outcomes in the previous 
round. They were also shown their response from the second 
round.
Each round was open for 4 weeks. A reminder email was 
sent to participants who had not completed the round after 2 
weeks and then again at 3 weeks. The final reminder asked if 
participants were experiencing difficulties in completing the 
questionnaire or if they had decided not to participate further in 
the study. Participants who completed round 1 were invited to 
complete both round 2 and round 3. A newsletter was sent to all 
participants in between all rounds to update them on progress 
and modifications.
Outcomes that were prioritised during the Delphi process 
were discussed and voted on at a face-to-face consensus meeting. 
Electronic voting was used to maintain anonymity (Response-
Card, Turning Technologies, Belfast, UK). An initial vote, In, 
Out or unsure, was followed by debate among participants, 
refinement of the wording of the consensus statement and then 
a second vote of in, out or unsure.
Outcome scoring and consensus deinition
Outcomes were carried forward between rounds if more 
than >70% of all participants scored them as really important 
(79). Each outcome was assessed for heterogeneity between 
the panels using a histogram depicting median scores. In 
Table 2 Voting across rounds
Voting demographics
Panel round 1 round 2 round 3 Consensus meeting (n)
SuRa (n/N (%)) Surgeons 39/47 (83) 39/39 (100) 39/39 (100) 12
Radiologists 21/27 (78) 21/21 (100) 21/21 (100) 4
GaNu (n/N (%)) Gastroenterologists 44/59 (75) 44/45 (98) 44/44 (100) 12
Nurses 17/22 (77) 15/17 (88) 15/15 (100) 5
Pa (n/N (%)) Patients 66/83 (80) 57/66 (86) 59/64 (92) 14
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addition, during each round, participants were given the 
opportunity to comment on the clarity and appropriateness 
of each outcome. All comments were reviewed by the study 
management group, and outcomes were modified to improve 
clarity if necessary.
At the end of each round, the study management group 
discussed all outcomes below the threshold for inclusion. The 
discussion was based on heterogeneity and any comments 
that had been recorded by the participants. Modification and 
frequently asked comments were sent to all participants using a 
newsletter in between rounds.
At the consensus meeting, participants were presented 
with the round 3 results and asked to vote prediscussion on 
whether they believed an outcome should be included in the 
COS, not included in the COS or whether they were unsure. 
Participants were then asked to advocate either for inclusion 
or exclusion of an outcome, before repeating the voting. 
Those where 70% of participants voted for their inclusion 
were retained in the COS.
ethical considerations
The local research and development department deemed 
the project to be service evaluation and therefore review by 
a National Health Service Research Ethics Committee was not 
necessary. The stakeholders were provided with information 
prior to registering to participate and throughout the process 
via newsletters. Consent to participate in the study was implied 
through completion of demographic questionnaires and volun-
tary attendance at the final meeting. Stakeholders were able 
to withdraw from the study at any time either by contacting 
the study team or by simply not responding to any of the 
questionnaires.
resulTs
Protocol modiications
Following the analysis of the round 2 of the Delphi process, it 
2857 references identified
through searching embase &
medline using the ovid
interface
No additional records
identified through
other sources
2857 references imported for screening
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949 duplicates removed
1654 studies excluded
205 studies excluded
-
-
-
-
-
-
-
-
141 Abstract only
30 Wrong study design
16 Duplicate
7 article not in english
6 wrong time period
3 £10 patients with CD PAF
1 duplication of patient cohort
1 unable to extract data
1908 studies screened
254 studies assessed for full-text
eligibility
49 studies included
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram of studies considered for the systematic review. CD, Crohn’s 
disease; PAF, perianal istula.
Table 3 Number of outcome measures reported and completeness of 
outcome reporting in perianal Crohn’s istula studies
randomised 
studies (n=10)
non-randomised 
studies (n=39)
Year
  2010–2011 2 15
  2012–2013 2 11
  2014–2016 6 13
Intervention
  Medical 5 18
  Surgical 4 14
  Combination 1 7
Number of patients with istula
  <50 3 22
  50–100 5 4
  >100 1 3
  NR 1 9
Number of outcomes measures
  <5 3 18
  5–10 6 20
  >10 1 1
Meets all core criteria for completeness of 
outcome reporting (%) 50.0 12.80
NR, not recorded.
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was identified that that panel colorectal surgeons and radiolo-
gists (SuRa) were the most discriminatory and the panel patient 
was the least discriminatory. Using the prespecified criteria, only 
6/79 (7.6%) outcomes were below the threshold for exclusion 
for the patient panel compared with 45/79 (57.0%) from the 
most discriminatory panel (SuRa) (online supplementary file 2).
The criteria for retention in the second round of the Delphi 
process were therefore modified, so that not only were outcomes 
where >70% participants overall scored them 79 retained but 
also those which >90% of the patient panel had scored them 
79 were carried forward to phase 3. In addition, four outcomes 
(online supplementary file 2) were retained by the study manage-
ment group as they were felt to be of key importance and would 
benefit from further evaluation and discussion.
High patient scoring and a change to the protocol in round 2 
meant the study management group decided that no outcomes 
were to be excluded in round 3. Analysis of round 3 confirmed 
the decision as again the 70% cut-off was deemed insufficiently 
discriminatory (online supplementary file 3). This allowed for 
the participants in the consensus meeting to be given the oppor-
tunity to see all the remaining outcomes.
Participants
A total of 238 participants registered their interest. Of these, 
187/238 participants (78.5%) registered their demographics and 
completed round 1 of the Delphi survey. One hundred and seven-
ty-six out of 187 participants (94.1%) completed round 2 and 
183/187 participants (97.9%) completed round 3. In total, 47 
participants attended the face-to-face meeting across the panels 
(16 from panel SuRa, 17 from panel gastroenterologists and IBD 
specialist nurses (GaNu) and 14 from panel patients (Pa)). Demo-
graphic details for each stakeholder group are summarised in 
tables 1 and 2.
Information sources and domain categorisation
A total of 2857 titles were identified, of which 949 were dupli-
cates and the remaining 1908 were screened. Of these, a further 
1654 studies were excluded based on title and abstract review. 
Following full-text review, a further 205 papers were excluded 
for the following reasons: only the abstract could be found, 
non-prospective study design, non-English language publica-
tions or not having a sufficient number of patients with Crohns 
fistula receiving treatment. This resulted in 49 included studies 
(figure 1). No additional papers were identified from systematic 
reviews or other trials. In total, 18 of the studies (37%) were 
prospective cohort studies (including two studies where data 
were retrospectively analysed from a prospectively collected 
database), 18 (37%) were systematic reviews and meta-analyses, 
9 (18%) were randomised controlled trials and the remainder 
were non-randomised studies. The median number of study 
participants with Crohns perianal fistula who received treat-
ment was 29 (IQR 1768).
There were 295 different clinical outcomes reported, with 
studies reporting a median of six (IQR 37) outcomes; these 
are summarised in table 3. The three most commonly reported 
RXWFRPH PHDVXUHV LQ WKH VWXGLHV ZHUH  RI WUDFWV QRW
draining on clinical examination (22 studies; 45%), Perianal 
Disease Activity Index (20 studies; 41%) and Crohns Disease 
Activity Index (CDAI) (table 4). No single outcome was reported 
in every study. The individual studies and the quality of outcome 
reporting were assessed using the five core questions proposed 
by Harmans criteria 22 in online supplementary file 4. Dupli-
cate and analogous terms were merged to form 89 unique 
outcome domains. Eleven further outcomes were generated 
through a combination of patient interviews and the PPI day. 
The study management group added a further six. The resultant 
106 outcomes were reviewed by the study management group, 
and 14 were excluded as they were felt to be applicable only to 
luminal disease, resulting in 92 unique outcomes that entered 
round 1 of the Delphi process. A summary of outcomes used in 
the online Delphi process with their lay definitions, organised 
according to themes, is presented in table 5.
Outcome prioritisation
The 92 outcomes were reviewed by participants in round 1, 
which generated 201 individual comments. The study manage-
ment group retained nine outcomes having altered the name 
(or lay description), due to polarising views/heterogeneity or 
comments by participants, implying a lack of clarity (online 
supplementary file 5). Five de novo outcomes were added, and 
18 outcomes were excluded according to the preset criteria. At 
the end of round 1, interim analysis demonstrated that the top 
10 outcomes rated by the panels were similar and are seen in 
table 6.
Of the 79 outcomes that entered round 2, 41 were below 
the preset threshold for exclusion. After a modification to the 
protocol, 12 of these were retained (eight due to high patient 
scoring and four by the study management group, as described 
above), which resulted in 29 (36.7%) being dropped from round 
2 (online supplementary file 2). The resultant 49 outcomes 
entered into the third round, and all were taken forward to the 
face-to-face consensus meeting (table 7). The process is described 
in figure 2, and individual scores for each round are in online 
supplementary files 24.
Consensus meeting
Following scoring at the consensus meeting, eight outcomes were 
retained in the COS. This constituted three patient-reported and 
five clinician-reported outcome domains (box 2).
The outcome radiological outcome was felt to be important by 
the attendees at the consensus meeting but did not meet criteria 
for retention in the COS after consensus discussion. Attendees 
main reason for excluding the outcome was that the cost asso-
ciated with MRI was likely to prohibit its use in research across 
both low-income and high-income countries and that it was 
therefore not appropriate for inclusion in a COS.
The meeting attendees did however note that it should be 
recommended for use as an outcome in all studies where it was 
feasible to do so.
At the consensus meeting, the individual outcomes in the 
impact on life theme did not meet universal consensus but 
were scored very highly by the patients and advocated for by 
them. Members of other panels felt the inclusion was important 
but were unable to differentiate the importance between them. 
As such, after a unanimous decision, it was decided that an 
Table 4 The most commonly outcome measures reported
Outcome measures in the included studies
number of 
studies
≥50% tracts not draining on clinical examination 22
Perianal Disease Activity Index 20
Crohn’s Disease Activity Index 19
Closure of external opening 17
No drainage either spontaneously or on gentle inger pressure 12
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Table 5 Outcome domains identiied through phase 1 with lay deinitions
Themes Outcome lay deinitions
Fistula response to 
treatment (symptoms)
≥50% tracts not draining on clinical examination More than half the openings on the bottom are dry and not oozing anything.
Closure of internal opening The hole inside the bottom (as opposed to on the buttock skin surface) closes. This must be assessed by a doctor.
Rectal mucosal healing An assessment of the last part of your intestine in clinic assessed by inserting a small probe into your bottom.
Complete istula healing assessed clinically An assessment of the bottom in clinic where all the opening/holes on the skin have closed on ≥2 consecutive clinic appointments (ie, assessed 
more than once).
Partial istula healing assessed clinically An assessment of the bottom in clinic where there is a decrease in the size/number of istula and a reduction in drainage.
Closure of all the external openings on clinical examination An assessment of the bottom in clinic where all the opening/holes on the skin have closed on a single examination (ie, assessed once).
Clinical assessment of drainage either spontaneously or on gentle inger pressure An assessment of the bottom in clinic where the doctors press around the openings on the bottom to look for discharge and also ask the patient 
about the drainage from their istulae.
Local perianal inlammation/induration assessed clinically An assessment of the bottom looking for acute inlammation around the istula (swelling and redness) and chronic inlammation (scarring and 
shrinking of the anal opening).
A validated score to assess perianal disease activity, for example, Perianal Disease Activity Index A scoring system used to assess whether the perianal disease is active and laring up or stable.
Development of perianal features of Crohn’s disease (other than istula) Developing skin tags, anal stenosis (narrowing), anal issures, ulcers or cancer.
Patient-reported reduction in istula drainage The patient saying there has been a decrease in the oozing/draining from the openings on the bottom.
Direct impact of istula on 
the patient
Incontinence to wind Unable to stop wind/latulence/gas escaping from your bottom.
Mucus leakage Unable to stop mucus coming out from your bottom.
Recurrence of istula The same istula hole that closed opens up again (the hole inside the bottom or the hole on the buttock skin surface).
Development of a new istula A new perianal istula develops in another place; that is, a new hole forms on the buttock skin surface or deeper inside the bottom after the 
intervention.
Perianal abscess on clinical assessment after intervention An abscess (collection of pus/infection) or lumps in the bottom area that forms after treatment.
Wound infection Increasing pain, redness, swelling in the wound requiring antibiotics (without an abscess).
An incontinence score A scoring system used over time to assess change in continence/bowel motion (consistency/frequency).
Incontinence to liquid stool Unable to stop liquid stool escaping from your bottom.
Incontinence to solid stool Unable to stop stool/faeces escaping from your bottom.
Pads for continence/leakage Needing to use pads inside underwear to soak up liquid discharge/oozing from the istula.
Plug for continence/leakage Needing to use anal plugs to soak up liquid discharge/oozing from the istula.
#Discrimination between passing stool and gas Unable to know whether you have passed wind/latulence/gas or whether you have passed faeces/stool.
Tenesmus or incomplete evacuation Feeling like you need to go to the toilet all the time (even if just been).
Anal bleeding Blood coming out of the bottom area (either from the istula or the bowel).
Anal pain Pain around the bottom.
Increased frequency of loose stool Runnier bowel motion and having to empty bowels more often than before.
Perianal related hospitalisation Being admitted to hospital because of your perianal Crohn’s disease, such as an abscess.
Surgical reintervention Another operation is needed after the irst treatment.
Faecal diversion or proctectomy Operation to remove the rectum (last part of the bowel) and/or having a stoma bag itted.
Faecal urgency Inability to delay going to the toilet/defecation for 15 min.
Continued
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Themes Outcome lay deinitions
Impact on the patient as 
a person
Lifestyle alterations (pain/restriction of activities) Change in lifestyle because of the istula.
Limitation to moderate activities Dificulty performing tasks such as light housework.
Limitation to vigorous activities (eg, running, lifting heavy objects, participating in strenuous sports) Unable to run, lift heavy objects, participate in strenuous sports.
Change in general health—physical Change in physical ability to do things.
#A quality of life score, for example, Short Form Survey 36 A scoring system that patients ill out to assess the various aspects of a person’ s life.
Change in general health—psychological Change in thought and feelings.
Lethargy and fatigue Exhausted, tired because of the istula.
Social interaction avoidance Stop leaving the house unless you have to (going to work and medical appointments but not going to see friends or going to parties/celebrations).
Anxiety and worries Anxious or worried about impact of the istula.
Feeling depressed and down, and hopelessness Feeling depressed and down, and hopelessness.
Irritable, frustrated and angry Feeling irritable, frustrated and angry.
Concern over further intervention Concerns over needing more treatment (having just had one type of treatment).
Sleep disturbance Having to get up at night due to toileting needs, soiling sheets, underwear change and so on.
Modifying how you walk, sit or stand because of your istula* Sitting on one buttock rather than both, standing as sitting is too painful or having to walking with your legs wider apart.
Modifying travel* Choosing modes of transport depending on access to the toilet (eg, train) or planning car journeys around toilet stop-offs.
Body detachment* Feeling ‘medicalised’ and that rather than yourself you are a ‘body’ on which medical treatment is performed.
A feeling of being unhygienic* Feeling unclean, dirty and unhygienic (rather than actual being unclean, dirty and unhygienic).
Concerns about and impact on fertility, birth, parenthood and family* Worried about getting pregnant in the irst place, about actually going through labour, keeping up with busy children and inability to give them 
everything because of limitation of the disease (eg, not being able to go for long walks).
Restriction of sexual activity Unable to have sex or be physically close to someone.
Physically restricted in self care Unable to wash, get dressed or look after yourself without help from someone else because of the istula.
Patient perception of continence compared with others or baseline A difference/change in continence compared with other people or how you used to before the istula.
Tolerability of treatment An overall assessment of how ‘acceptable’ a treatment is; for example, does it have so many side effects that you want to stop it?
Decisional regret of treatment choice A measure of regret of choosing a speciic treatment option whether (medical or surgical).
Avoidance of intimacy* Avoiding getting too close with another person (hugging, sitting next to each other and so on) due to fears that you smell or they might know 
that you have a istula. This includes getting into new relationships.
Unable attend school/work Cannot go to school/college/university or do your usual job because of perianal istula due to need to be off at short notice.
Change in lifestyle based on toileting needs Go out less or only go to places where you know there is a clean toilet and washing facilities because of perianal istula. Or take spare clean 
underwear and wipes with you when you go out.
Restricted in what you wear* Being unable to wear tight clothing and wearing baggy clothes to reduce pain, conceal bulging pads or bulky gauze inside underwear. Also 
wearing dark clothing to conceal stains.
Embarrassment and feeling isolated* Feeling conscious of the istula, which subsequently affects the way I walk/behave/interact with the world, which is obvious to others and leaves 
me embarrassed so that I alter what I do.
Assessment with imaging 
techniques (scans)
#MRI assessment of istula volume Calculating the size of istula on an MRI scan to generate a number, and then comparing the size/number over time.
Fistula response on endoanal ultrasound A rectal probe is inserted into the bottom to look for and assess the istula using an ultrasound machine to see if the istula is better/worse/the 
same.
Abscess on MRI following treatment A collection of pus on MRI scan.
T1 enhancement on MRI A speciic way to assess inlammation within a istula on a MRI (it adds time to a normal MRI but allows doctors to better decide what is istula 
and what is blood vessel).
Hyperintensity on T2-weighted MRI A speciic way to assess inlammation within a istula on an MRI—this is standard care.
MRI assessment of rectum (proctitis) Looking for inlammation of the rectum (last part of the intestine/bowel) on MRI.
Fistula response on MRI imaging The istula looks ‘better’ or ‘about the same’ or ‘worse’ on MRI.
#An activity based MRI score, for example, Van Assche Score A scoring system used by radiologists (MRI doctors) to assess whether a istula is ‘active’, that is, acute inlammation or nearer to the other end of 
the scale of healing.
Table 5 Continued 
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Themes Outcome lay deinitions
Fistula response to 
treatment (tests)
Time to loss of response to medical treatments The length of time taken before you develop resistance to a medication (biologicals/anti-TNF).
Objective blood markers of inlammation Blood tests looking for inlammation.
C reactive protein A speciic blood test looking for inlammation.
Non-inlammatory blood markers (related biologicals) Blood tests looking for other things, such as anaemia, B12 levels and so on.
Instability of weight (assessed by body mass index (BMI)) Putting on weight or losing weight, assessed using BMI (a score based on weight and height).
Fever Feeling ‘hot’ and feverish/getting ‘the chills’ with a high temperature.
Safety implications related 
to treatment
Nausea or vomiting Feeling sick or vomiting after treatment.
Death Death as a result of a treatment.
Rash or other skin/hair problems Changes in the skin (rash, dryness, acne and so on), hair thinning or hair loss.
Allergic reaction A reaction to a treatment (ranging from a rash to swelling of the throat).
Cardiorespiratory complications Complications of treatment related to cardiovascular system—heart attacks and abnormal heart rhythms.
Neurological complications Complications of treatment related to nervous system—visual symptoms, headaches and nerve damage.
Urinary complications Complications of treatment related to urinary system—waterworks infections, damage to the any of the anatomical structures during surgery.
Grading system for surgical complications, for example, Clavien-Dindo A generic validated grading system of all complications related to surgery (covers all systems—cardiovascular, neurological and so on).
Safety (adverse events) and toxicity Measuring how safe and tolerable a given treatment is.
Surgical complications speciic to the surgical procedure (eg, plug extrusion) Speciic surgical complications, for example, plug extrusion (following anal plug insertion).
#Medical complications speciic to the immunosuppression (eg, opportunistic infections and cancers) Increased risk of cancer (eg, lymphoma) and an increased risk of any infection as a result of being on an immunosuppressive medication (anti-TNF/
biologicals/thiopurines).
Impact on the patient 
over time
Duration of healing/improvement How long the treatment helped you to feel better for.
Biological-free remission Period of time not needing to take biologicals/anti-TNFs (eg, inliximab/remicade, humira/adalimumab).
Cost-effectiveness A measure of how effective the treatment has been but also factoring in the cost of this treatment.
Increasing analgesia* Needing more painkillers to get through the day.
Antibiotic-free remission* Period of time not needing to take antibiotics.
Use antidiarrhoeal drugs Taking medication to make the stool less runny (eg, loperamide).
Recovery time after intervention Length of time off work/study after treatment intervention.
Financial implications* Financial hardship including loss of income, career stagnation, extra expenses, for example, buying pads, clean underwear and so on.
Origin From SR (n=76)
Added from patients (n=11)*
#Added from SMG (n=5)
Excluded by the SMG 
(n=14)
Faecal calprotectin Not speciic to perianal Crohn’s disease and more to luminal disease.
Steroid-free remission Not speciic to perianal Crohn’s disease and more to luminal disease.
Abdominal discomfort Not speciic to perianal Crohn’s disease and more to luminal disease.
Dietary supplements as oral intake low Not speciic to perianal Crohn’s disease and more to luminal disease.
A validated Crohn’s disease activity score Not speciic to perianal Crohn’s disease and more to luminal disease.
Remission of Crohn’s disease Not speciic to perianal Crohn’s disease and more to luminal disease.
Identiication of endoscopic signs suggestive of failure of treatment (relating to systemic/overall Crohn’s disease) This relates to luminal relapse, and we have included assessment of the rectal mucosa separately.
MRI features (luminal) Not speciic to perianal Crohn’s disease and more to luminal disease.
Abdominal mass Not speciic to perianal Crohn’s disease and more to luminal disease.
Extraintestinal manifestations of Crohn’s disease Not speciic to perianal Crohn’s disease and more to luminal disease.
Comparison with other individuals (luminal) Not speciic to perianal Crohn’s disease and more to luminal disease.
Haemorrhage Not speciic to perianal Crohn’s disease and more to luminal disease.
Feasibility of technique Not speciic to perianal Crohn’s disease and more to luminal disease.
Decrease in size of istula Deinition unclear and not deined within the study. Likely to have covered through other forms of clinical assessment (consensus to remove).
*Added from patients (n=11).
#Added from SMG (n=5).
SMR, study management group; SR, systematic review; TNF, tumour necrosis factor.
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individual outcome making up this overarching domain should 
be voted on and prioritised by patients alone.
DIsCussIOn
This is the first study to standardise outcome reporting in fistu-
lising pCD. An exhaustive list of candidate outcome measures 
was generated through a systematic review of contemporary 
outcomes, together with patient views. Using an online tool, 
a large number of stakeholders were able to participate in a 
pragmatic Delphi consensus process that ensured emphasis on 
patient perspective and clinical relevance. Consensus voting and 
discussion generated a COS that all stakeholders supported with 
applicability to all study designs. The aim is to improve research 
and to use this COS as an impetus to drive improvement in 
clinical management within the field. The COS allows measure-
ment of outcomes for all cohorts of adult patients with pCD, 
regardless of disease state, the intervention under assessment or 
the presence of luminal disease. In this study, we established an 
eight-domain COS for use in studies evaluating interventions 
in fistulising pCD. A two-domain radiological module is also 
strongly advocated for use wherever possible.
Fistulising pCD denotes a severe and disabling disease course 
characterised by the need for multiple hospitalisations and opera-
tions. It also has a high economic cost, particularly with the use of 
biological agents as the mainstay of treatment.2326 The James Lind 
Alliance, a national Priority Setting Partnership group of patients and 
clinicians, identified pCD and specifically the individual factors that 
influence various treatment strategies and outcomes as one of the 
Top 10 unanswered questions in the field of IBD.27 However, the 
criteria by which success is measured in the management of Crohns 
perianal fistula have hitherto been a challenge to researchers.28 Most 
studies have used a measure of the degree of clinical healing as their 
primary outcome; however, deep tissue healing has been shown to 
lag behind simple closure of the external openings29 and, crucially, 
success measured this way has generally been disappointingly poor. 
Moreover, if control of symptoms is the primary objective of treat-
ment, these measures are wholly inappropriate and will fail to 
demonstrate a benefit, even if patients perceive one. The multimodal 
treatment of perianal fistulas in Crohns disease: seton versus anti-
TNFα versus advancement plasty (PISA) trial group have proposed 
a set of primary outcomes, which aim to address this deficit.30 Of 
note, the primary outcome is pragmatic and clinically relevant, 
measuring reinterventions following treatment. The secondary 
endpoints include quality of life, disease activity and importantly use 
an MRI-based assessment to determine fistula closure as a long-term 
measure at 18 months. Recently, the first randomised controlled 
trial of stem cell therapy in fistulising pCD was published.31 The 
authors used a new composite primary endpoint, comprising clin-
ical and radiological healing, further revealing the lack of agreement 
on which fistula outcomes to use and also recognising the inade-
quacy of a single outcome measure to define success.
The International Consortium for Health Outcome Measure-
ment (ICHOM) has recently been published for IBC. It empha-
sises the importance of patient-reported outcome measures in 
IBD research but as it has been designed for IBD in general it has 
minimal information for patients with fistulas.32 This COS aims 
to address an unmet need in pCD where standardising outcome 
measurement is particularly difficult due to changes in the 
patients goals of treatment over time, the refractory nature of 
perianal disease compared with luminal disease and the specific 
symptoms associated with the condition.33 34
A strength of this study is that every stage of the process, 
including amalgamation, addition and exclusion of outcomes, 
was performed by consensus and always included patient 
representation. Examples include the interventional complica-
tions and morbidity, which featured in the outcomes presented 
on the consensus day but were excluded from the final COS, 
as the participants felt these would be reported as a minimum 
in the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses harms checklist.35 A similar discussion excluded 
death as an outcome. The initial design of this study followed 
the guide set by the OMERACT36 group, but at the consensus 
meeting, it was felt that death was less suitable for this COS 
and a more relevant hard endpoint would be faecal diversion. 
Another consensus decision was that of an optional imaging 
module, but because MRI is not universally accessible, it did not 
reach threshold for inclusion as a mandatory outcome measure. 
Another strength was the diversity in the study management 
group with stakeholder leads and methodologists from a 
number of different institutions and geographical locations, and 
the crucial stakeholders (patients) were always prioritised. For 
Table 6 Top 10 outcomes voted after phase 1
Item Outcomes
Panel sura 
high
Panel sura 
low
30 Faecal diversion or proctectomy 97 0
75 Death 97 3
15 Development of a new istula 89 0
20 Incontinence to solid stool 89 0
28 Perianal-related hospitalisation 89 0
29 Surgical reintervention 89 2
14 Recurrence of istula 86 0
16 Perianal abscess on clinical assessment after 
intervention 86 2
56 Unable attend school/work 84 0
19 Incontinence to liquid stool 83 0
Panel Ganu 
high
Panel Ganu 
low
75 Death 100 0
30 Faecal diversion or proctectomy 98 0
15 Development of a new istula 97 0
84 Medical complications speciic to the 
immunosuppression (eg, opportunistic 
infections and cancers) 97 0
14 Recurrence of istula 94 0
20 Incontinence to solid stool 94 0
28 Perianal-related hospitalisation 94 0
19 Incontinence to liquid stool 92 0
56 Unable attend school/work 92 0
21 Pads for continence/leakage 91 0
Panel Pa 
high
Panel Pa 
low
19 Incontinence to liquid stool 96 0
30 Faecal diversion or proctectomy 96 0
20 Incontinence to solid stool 93 1
16 Perianal abscess on clinical assessment after 
intervention 92 6
15 Development of a new istula 92 0
28 Perianal-related hospitalisation 91 3
75 Death 91 5
17 Wound infection 90 0
39 Social interaction avoidance 89 6
29 Surgical reintervention 86 5
Panel GaNu, gastroenterologists and IBD specialist nurses; panel Pa, patients; panel 
SuRa, colorectal surgeons and radiologists. 
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example, we found that patients tended to rank most outcomes 
highly, gastroenterologists slightly less so and surgeons least 
of all. This meant that the outcomes that fell below the inclu-
sion bar tended to do so as a result of the views of the clini-
cians, rather than the patients, potentially deviating from the 
aim of a patient-centred COS. There is currently no guidance 
on how to discuss outcomes with patients and carers in qual-
itative research,37 but in efforts to ameliorate this effect, the 
study management group used separate thresholds for clini-
cians and patients to allow for prioritisation of outcomes scored 
Table 7 Outcomes to be included in the COS at the consensus meeting
Question
% In
Overall (%)
Patient vote 
alone (%)
Final 
consensusPanel sura (%) Panel Ganu (%) Panel Pa (%)
1 Patient-reported reduction in istula drainage 57.1 53.3 30.0 46.8
2 Development of other perianal features 53.8 73.3 70.0 65.7
3 Complete istula healing assessed clinically 53.3 40.0 44.4 45.9
4 Validated score to assess perianal disease activity 100.0 93.8 77.8 90.5 IN
5 Development of a new istula 69.2 83.3 87.5 80.0 IN
6 Incontinence to solid stool 26.7 33.3 40.0 33.3
7 Pads for continence/leakage 26.7 40.0 40.0 35.6
8 Recurrence of istula 85.7 68.8 80.0 78.2
9 Perianal abscess on clinical assessment after intervention 86.7 100.0 90.0 92.2 IN
10 Incontinence to liquid stool 71.4 93.3 100.0 88.3 Combined†
11 Perianal-related hospitalisation 35.7 50.0 10.0 31.9
12 Faecal diversion or proctectomy 100.0 100.0 100.0 100.0 IN
13 Wound infection 0.0 0.0 30.0 10.0
14 Anal pain 66.7 87.5 90.0 81.4
15 Discrimination between passing stool and gas 6.7 33.3 12.5 17.5
16 Surgical reintervention 93.3 93.8 80.0 89.0 IN
17 Anal bleeding 0.0 14.3 60.0 24.8
18 Reversal of defunctioning stoma 33.3 37.5 22.2 31.0
19 A global assessment of incontinence that covers all aspects of leakage 92.9 100.0 100.0 97.6 IN
20 Fistula response on MRI 85.7 86.7 80.0 84.1 IN
21 Hyperintensity on T2-weighted MRI 46.7 38.5 62.5 49.2
22 MRI assessment of istula volume 35.7 53.8 55.6 48.4
23 Fistula T1 enhancement on MRI 13.3 45.5 60.0 39.6
24 Abscess on MRI following treatment 66.7 87.5 60.0 71.4
25 An activity-based MRI score 86.7 93.3 88.9 89.6 IN
26 A global quality of life score 100.0 93.8 100.0 97.9 n/a IN
27 Physically restricted in caring for oneself 15.4 26.7 70.0 37.4 70.0
28 Change in lifestyle based on toileting needs 23.1 53.3 87.5 54.6 90.0 IN
29 Embarrassment and feeling bloated 25.0 42.9 60.0 42.6 60.0
30 Unable to attend school/work 36.4 86.7 100.0 74.3 100.0 IN
31 Restriction of sexual activity 58.3 80.0 90.0 76.1 100.0 IN
32 Lethargy and fatigue 0.0 20.0 66.7 28.9 60.0
33 Limitation to moderate activities 8.3 12.5 30.0 16.9 40.0
34 Change in general health 16.7 64.3 80.0 53.7 80.0
35 Avoidance of intimacy 36.4 60.0 88.9 61.8 88.9 Combined‡
36 Anxiety and worries 8.3 25.0 55.6 29.6 75.0
37 Change in physical ability to do things 0.0 12.5 77.8 30.1 80
38 Feeling depressed, down, hopeless, unable to cope 7.7 42.9 90.0 46.8 90 IN
39 Modifying how you sit, walk and stand because of your istula 33.3 57.1 70.0 53.5 80
40 Lifestyle alterations (pain/restriction) 25.0 53.8 80.0 52.9 100 IN
41 Social interaction avoidance 50.0 46.2 70.0 55.4 80
42 Duration of improvement 53.8 80.0 88.9 74.2
43 Death 46.2 42.9 55.6 48.2
44 Allergic reaction 7.7 6.7 37.5 17.3
45 Safety (adverse events) and toxicity 7.7 7.1 50.0 21.6
46 Urinary complications 38.5 76.9 77.8 64.4
47 Cardiorespiratory complications 7.7 0.0 44.4 17.4
48 Neurological complications 0.0 8.3 60.0 22.8
49 Medical complications speciic to immunosuppression 0.0 15.4 44.4 19.9
*‘Patient Priorities’ - consensus agreement by all to allow these items to be voted on by patient alone.
†Combined with ‘A global assessment of incontinence that covers all aspects of leakage’.
‡Combined with ‘Restriction of sexual activity’.
COS, core outcome set.
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particularly highly by the patients. In addition, some outcomes 
seemed to score poorly despite very similar outcomes scoring 
highly. This was taken as evidence of poorly worded descrip-
tions or concepts difficult to explain in pithy prose. For example, 
the concept of a global assessment of quality of life reached the 
threshold for exclusion in the online Delphi but was discussed 
at the consensus meeting for the reasons above and was selected 
as part of the final COS once it was adequately explained to the 
patients by whom it was then championed.
A limitation of this study is that all the participants were based 
in the UK, which could potentially affect generalisability to other 
populations, especially in low-income countries. There was an 
active decision by the study management group to minimise 
attrition through the rounds and to achieve maximum recruit-
ment. One missing stakeholder was industry; this was discussed 
and specifically excluded due to concern about potential bias. 
An online survey was chosen due to its ease of use, increasing 
the feasibility of national sampling, as well as removing inter-
view bias.38 To date, this study has one of the largest numbers of 
participants and one of the lowest attrition rates.
Given the poor rates of fistula closure experienced by most 
patients, the range of new medical and surgical treatments emerging 
and the high cost of many of them determining their relative effi-
cacy and cost effectiveness is important. Comparison of different 
techniques from different studies mandates standardised outcome 
reporting, which this COS will provide. Outcomes specific to a given 
study as a result of the technique used or population studied, such as 
the rate of plug extrusion, or complications relating to immunosup-
pression, remain important to measure and are not excluded by a 
COS. Innovation, progress and pragmatism will require researchers 
to measure other outcomes, but in order to appraise interventions 
completely and ensure relevance to patients, a COS should also be 
used. Although MRI is crucial to determine deep tissue healing, its 
value in the assessment of symptom palliation is less clear, and it 
is not readily available to all studies or institutions, so it could not 
be considered a core outcome but is a strongly advocated addition 
where appropriate.
The Evaluating goal-directed management of fistulising peri-
anal Crohns disease research group is building a portfolio of 
foundation research, of which this COS is a central part. This 
COS requires international validation if it is to be used outside 
the UK. It is also necessary to develop a core measurement 
set, a collection of measurement tools and standards by which 
these outcomes can be assessed in a given study. For example, 
there is no validated, disease-specific, patient-derived quality of 
life measurement tool for Crohns anal fistula. This is another 
unmet need described by the European Crohns and Colitis 
Organisations consensus group.20 Creation of such a measure-
ment tool is underway, and development of a core measurement 
set to complement this COS is also underway.
COnClusIOn
Using rigorous methodology and representative stakeholder 
engagement, we have generated a COS for use in fistulising pCD 
studies. Groups assessing treatment in fistulising pCD should be 
strongly encouraged to adopt and use this COS to reduce the 
heterogeneity of outcome reporting and improve the quality and 
comparability of future research.
Twitter @KSahnan @StMarksHospital @cOMetinitative @StMarksFrU @
philtozer1 @azminaVerjee @angusgKMcnair @DanHind1 @wannabehaweye @
stevebrownsheff @DrailsaHart @acPgBi @BritSocgasto @BDrF1 #crStrials
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Figure 2 Outcome low diagram. COS, core outcome set; PPI, patient 
and public involvement.
box 2 Core outcome set for istulising perianal Crohn’s 
disease
Patient-reported outcomes
 Ź Global assessment of quality of life.
 Ź Combined score of patient priorities.
 – Lifestyle restriction (general)
 – Lifestyle restriction based on toileting needs
 – Depression
 – Inability to attend school/work
 – Restriction of sexual activity and avoidance of intimacy.
 Ź Global assessment of incontinence.
Clinician-reported outcomes
 Ź A validated score to assess perianal disease activity.
 Ź Development of a perianal abscess.
 Ź Development of a new/recurrent istula.
 Ź Unplanned surgical reintervention.
 Ź Faecal diversion or proctectomy.
Imaging (optional module)
 Ź Fistula response on MRI.
 Ź An activity-based MRI score responsive to change.
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